Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Current ADC Linker Chemistry

10 Mar 2015

Abstract excerpt

The list of ADCs in the clinic continues to grow, bolstered by the success of first two marketed ADCs: ADCETRIS® and Kadcyla®. Currently, there are 40 ADCs in various phases of clinical development. However, only 34 of these have published their structures. Of the 34 disclosed structures, 24 of them use a linkage to the thiol of cysteines on the monoclonal antibody. The remaining 10 candidates utilize chemistry...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Click Chemistry and Applications
Share to HER2/EGFR in Cancer Research
Share to Monoclonal and Polyclonal Antibodies Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 25759187
DOI: 10.1007/s11095-015-1657-7

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Current ADC Linker ChemistryPMID 25759187Read ↗

Linker Design in Antibody-Drug Conjugates: Balancing Stability, Release and ResistanceSemantic proximity Read ↗

Harnessing a catalytic lysine residue for the one-step preparation of homogeneous antibody-drug conjugates.Semantic proximity Read ↗

Single Mutation on Trastuzumab Modulates the Stability of Antibody-Drug Conjugates Built Using Acetal-Based Linkers and Thiol-Maleimide Chemistry.Semantic proximity Read ↗

Peptide-Drug Conjugates as Next-Generation Therapeutics: Exploring the Potential and Clinical ProgressSemantic proximity Read ↗

Antibody and antibody fragments Site Specific Conjugation using New Q-tag Substrate of Bacterial Transglutaminase.Semantic proximity Read ↗

TUB-010, a novel anti-CD30 antibody-drug conjugate based on Tub-tag technology, widens the therapeutic window by reducing toxicity while maintaining high efficacySemantic proximity Read ↗

Introduction of Carbonyl Groups into AntibodiesSemantic proximity Read ↗

Homogeneity of antibody-drug conjugates critically impacts the therapeutic efficacy in brain tumorsSemantic proximity Read ↗

<i>In vivo</i> Auto-tuning of Antibody-Drug Conjugate Delivery for Effective Immunotherapy using High-Avidity, Low-Affinity AntibodiesSemantic proximity Read ↗

Expanding the repertoire of Antibody Drug Conjugate (ADC) targets with improved tumor selectivity and range of potent payloads through in-silico analysis.Semantic proximity Read ↗

Attachment Site Cysteine Thiol pKa Is a Key Driver for Site-Dependent Stability of THIOMAB Antibody-Drug Conjugates.Semantic proximity Read ↗

Self‐Assembled L–DNA Linkers for Rapid Construction of Multi‐Specific Antibody‐Drug Conjugates LibrarySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.